BioStock: Annexin comments on acquisition and focus on ANXV in ophthalmology
Merck recently announced that they are acquiring the biotech company EyeBio for up to 3 billion USD, thereby strengthening its presence in ophthalmology. EyeBio’s drug candidate Restoret is being developed to treat diabetes-related eye diseases. Another active player in the ophthalmology field is the Swedish company Annexin Pharmaceuticals. BioStock reached out to the company’s CEO Anders Haegerstrand to get his comments on the acquisition and gain further insights into Annexin’s focus for 2024.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se